Skip to main content

Table 1 Studies with negative results based on most recent trial

From: Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

Medication Relevant studies
Amiloride Positive results from open-label study (pilot study) [328]
Negative results from phase 2b clinical trial [317]
Biotin (MD1003, high dose) Positive results from three-centers study (pilot study) [321]
Positive results from phase 2 clinical trial [322]
Negative results from phase 3 clinical trial [323]
Dronabinol Negative results from randomized controlled trial [336]
Fingolimod Negative results from phase 3 clinical trial [265]
Fluoxetine Negative results from single-center study (pilot study with inadequate power) [337]
Negative results from phase 2b clinical trial [317]
Glatiramer acetate Negative results from randomized controlled trial [338]
Idebenone Negative results from phase 1/2 clinical trial [339]
Lamotrigine Negative results from phase 2 clinical trial [340]
Laquinimod Negative results from phase 2 clinical trial [341]
Lenercept Negative results from phase 2 clinical trial [342]
Lithium Negative results from open-label pilot study [343]
MBP8298 (dirucotide) Positive results in subgroup of participants from phase 2 clinical trial [344]
Negative results from phase 3 clinical trial [345]
MIS416 Negative results from phase 2 clinical trial from pharmaceutical company report [346]
Natalizumab Positive results from phase 2 clinical trial [347]
Negative results on sustained disability progression (positive results on upper-limb component of disability) from phase 3 clinical trial [348]
Opicinumab Negative results from phase 2 clinical trial [349]
Development of opicinumab has been halted by the pharmaceutical company (October 2020) [350]
Riluzole Positive results from pilot study [332]
Negative results from phase 2b clinical trial [317]
Rituximab Negative results from phase 2/3 clinical trial [351]